ABSTRACT
Objectives@#This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older. Using real-world data, the period during which the BN.1 Omicron variant was dominant was compared to the period dominated by the BA.5 variant. @*Methods@#In this retrospective cohort study, data were collected regarding 2,665,281 patients infected with severe acute respiratory syndrome coronavirus 2 between July 24, 2022, and March 31, 2023. Propensity score matching was utilized to match patients who received nirmatrelvir/ritonavir in a 1:4 ratio between BN.1 and BA.5 variant groups. Multivariable logistic regression analysis was employed to assess the effects of nirmatrelvir/ritonavir within these groups. @*Results@#Compared to the prior period, the efficacy of nirmatrelvir/ritonavir did not significantly differ during the interval of Omicron BN.1 variant dominance in the Republic of Korea. Among patients treated with nirmatrelvir/ritonavir, a significantly lower risk of mortality was observed in the BN.1 group (odds ratio [OR], 0.698; 95% confidence interval [CI], 0.557–0.875) compared to the BA.5 group. However, this treatment did not significantly reduce the risk of severe or critical illness, including death, for those in the BN.1 group (OR, 0.856; 95% CI, 0.728–1.007). @*Conclusion@#Nirmatrelvir/ritonavir has maintained its effectiveness against COVID-19, even with the emergence of the BN.1 Omicron subvariant. Consequently, we strongly recommend the administration of nirmatrelvir/ritonavir to patients exhibiting COVID-19-related symptoms, irrespective of the dominant Omicron variant or their vaccination status, to mitigate disease severity and decrease the risk of mortality.
ABSTRACT
Background@#Paxlovid is an oral antiviral drug that received emergency use authorization in South Korea for the treatment of patients with mild-to-moderate coronavirus disease 2019 (COVID-19) on January 14, 2022. Since the onset of the severe acute respiratory syndrome coronavirus 2 pandemic, the virus has continued to evolve. The emergence of new variants has raised concerns about possible reductions in the effectiveness of vaccines and drugs. The effectiveness of Paxlovid in patients infected with the omicron variant and subvariants has not yet been determined. This study assessed the effectiveness of Paxlovid at reducing the risk of severe/critical illness or death and death in patients with mild-to-moderate COVID-19 caused by omicron subvariant BA.5. @*Methods@#In this nationwide retrospective cohort study, data on 8,902,726 patients were collected from four sources (the Drug Utilization Review database, COVID-19 Patient Information Management System, confirmed patient information, and basic epidemiological investigation data) between July 1 and November 30, 2022. Multivariable logistic regression analysis was conducted, with adjustment for age, sex, severe acute respiratory syndrome coronavirus 2 immunity (vaccination), and comorbidities. @*Results@#A total of 1,936,925 patients with COVID-19 were included in the analysis, including 420,996 patients treated with Paxlovid, and 1,515,959 patients not treated with Paxlovid. Paxlovid treatment in patients aged ≥ 60 years of age was associated with significantly reduced risk of severe/critical illness or death (46.0%), and death rate (32.5%), and its effectiveness was high, regardless of vaccination status. @*Conclusion@#Paxlovid is effective at reducing the risk of death due to COVID-19 in patients with omicron BA.5 infection, especially in older patients, regardless of vaccination status. This suggests that older patients with COVID-19-related symptoms should be administered Paxlovid, regardless of their vaccination status, to reduce severity and risk of death.
ABSTRACT
BACKGROUND: In this study, we aimed to investigate the drinking behaviors and drinking-related problems of college students in South Korea to produce national alcohol statistics. METHODS: We carefully examined the questionnaires and previous research developed in the previous research project and selected questions that reflect the special environment and culture of college students. In order to stratify a nationally representative sample of college students, the distribution of students around the country were found through the educational statistics database of the Korea Educational Development Institute. Based on this information, we conducted a survey in collaboration with Gallup (Korea) to survey and analyze the drinking behaviors of 5,024 Korean students. RESULTS: A nationwide cross-sectional survey was conducted in 2017, for Korean college students. A total of 5,024 students were recruited and analyzed. The monthly drinking rate was 78.0% for male students and 72.9% for female students. The high-risk drinking rate was 23.3% for male students and 17.2% for female students. The most popular category for number of drinks per drinking session was ‘more than 10 glasses’ per drinking session for both male (44.1%) and female (32.8%). On the alcohol use disorders identification test, the greatest proportion of male students were in the high-risk drinking category (score 8 to 15) 43.8%, followed by the ‘low-risk drinking’ (score 0 to 7) in 43.6%, ‘alcohol abuse’ (score 16 to 19) 7.2%, and ‘alcohol dependence’ (greater than 20) 5.4% categories, respectively. For female students, the greatest proportion of female students were in the ‘low-risk drinking’ in 49.6%, followed by ‘high-risk drinking’ 37.1%, ‘alcohol abuse’ 8.4%, and ‘alcohol dependence’ 4.9% categories, respectively. CONCLUSION: The results of the study showed that the drinking behavior of Korean college students was excessive. Overall, it was found that the college population has a greater high-risk drinking behaviors than general adult population. Furthermore, these problem drinking behaviors were prominent among female college students. Results from the present study suggest that it is necessary to monitor the drinking behavior of college students with constant interest and to prepare policies and strategies suitable for these circumstances.